Does Humana Cover Amlodipine? Formulary, Prior Auth, and Appeals (2025)

What Is Amlodipine and Why Is Coverage Relevant?

Amlodipine is a long-acting dihydropyridine calcium channel blocker approved by the FDA for hypertension and angina. It is inexpensive as a generic. Most patients pay less than $15 per month at a cash-pay pharmacy, yet confirming Humana formulary placement still matters because some Medicare Advantage plans apply quantity limits, preferred pharmacy networks, and tier-based cost-sharing that can quietly raise out-of-pocket costs above the cash price.

The FDA first approved amlodipine (brand name Norvasc) in 1992 [1]. The generic became widely available in 2007, and today amlodipine is on the World Health Organization's List of Essential Medicines [2]. Hypertension affects approximately 47% of U.S. adults, according to the CDC [3], making amlodipine one of the most prescribed drugs in the country. Humana's coverage decisions for this drug affect millions of Medicare Advantage enrollees alone.

Amlodipine's mechanism involves blocking L-type calcium channels in vascular smooth muscle and cardiac muscle, reducing peripheral vascular resistance and myocardial oxygen demand [4]. The ASCOT-BPLA trial (N=19,257) demonstrated that an amlodipine-based regimen reduced the primary endpoint of nonfatal myocardial infarction and fatal coronary heart disease compared with an atenolol-based regimen (relative risk reduction 10%, P<0.0001 for all-cause mortality favoring amlodipine) [5]. Those efficacy data support why ACC/AHA hypertension guidelines list calcium channel blockers as first-line agents [6].

How Humana's Formulary Works for Amlodipine

Generic amlodipine appears on Tier 1 or Tier 2 of most Humana formularies, which means low or no copay. Tier placement and cost-sharing differ by plan type.

Humana administers dozens of distinct plan designs across commercial, Medicare Advantage (Part D), and Medicaid products. Each plan maintains its own formulary, called a drug list, that assigns every covered medication to a cost-sharing tier [7]. For Medicare Part D plans specifically, CMS requires that most generic hypertension drugs appear on the lowest cost-sharing tiers [8]. Amlodipine consistently meets that standard.

On Humana Medicare Advantage Prescription Drug (MAPD) plans reviewed for plan year 2025, generic amlodipine (2.5 mg, 5 mg, and 10 mg tablets) is listed as a Tier 1 preferred generic with a $0 copay at preferred network pharmacies for a 30-day supply and a $0, $3 copay for a 90-day supply through Humana Pharmacy or preferred mail-order. On commercial (employer-sponsored) plans, the tier placement is typically Tier 1 or Tier 2 depending on the employer benefit design, with copays ranging from $5, $15 for a 30-day supply.

Brand-name Norvasc, if a prescriber specifically requests it and dispenses as written, falls on a higher tier (Tier 3 or Tier 4 on most Humana plans) and will cost substantially more. Most plans apply a generic substitution rule: if a generic equivalent exists, the plan pays at the generic rate and the member pays the difference for brand if they insist on brand [9].

You can verify your specific plan's tier placement by using the Humana formulary search tool at humana.com or by calling the member services number on the back of your insurance card. CMS also publishes every Part D plan formulary at cms.gov [8].

Does Humana Require Prior Authorization for Amlodipine?

Prior authorization (PA) is not required for generic amlodipine on the vast majority of Humana plans. Exceptions exist for some high-dose prescriptions or specific HMO plan designs.

For standard doses (2.5 mg, 5 mg, and 10 mg tablets, one tablet daily), Humana does not apply prior authorization requirements on most of its commercial and Medicare Advantage formularies. This reflects CMS guidance discouraging unnecessary barriers for commonly prescribed, evidence-based generics [8]. The ACC/AHA 2017 hypertension guideline explicitly recommends thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers, including amlodipine, as first-line treatment for most patients [6].

A PA requirement may appear in three specific situations. First, if a prescriber writes for a quantity exceeding a standard 30- or 90-day supply in a single fill. Second, if the diagnosis code on the prescription does not clearly map to hypertension (ICD-10 I10) or angina pectoris (ICD-10 I20). Third, on certain Humana HMO plans that require PA for all medications above a low-cost tier as a plan-level cost-control measure [10].

When PA is required, the prescribing physician submits a PA request through Humana's provider portal or by fax. Humana is required by CMS to respond to standard PA requests within 72 hours and to urgent requests within 24 hours [11]. The PA criteria Humana typically evaluates include confirmed diagnosis, appropriate dosing range, and absence of a clinical contraindication to the drug class.

HealthRX PA Checklist for Amlodipine on Humana (for prescribers):

1. Confirm ICD-10 code I10 (hypertension) or I20.x (angina) is on the prescription and in the patient's chart.
2. Verify the requested dose is 2.5 mg, 5 mg, or 10 mg once daily. Doses above 10 mg per day are outside FDA-labeled dosing and will trigger automatic denial [1].
3. Document blood pressure readings or angina symptom history in the chart note attached to the PA request.
4. Submit via Humana's provider portal at provider.humana.com for fastest response; fax adds 24 to 48 hours of processing time.
5. If PA is denied at initial submission, request a peer-to-peer review with the Humana medical director within 24 hours of the denial notice.

Step Therapy Requirements for Amlodipine on Humana

Step therapy requiring a patient to try a different drug before amlodipine is rare for this drug, because generic amlodipine is already a first-line, low-cost option. Some narrow-network HMO plans do apply step therapy to calcium channel blockers if a patient has not first tried a generic thiazide diuretic such as hydrochlorothiazide or chlorthalidone.

JNC 8 and the 2017 ACC/AHA guideline both list calcium channel blockers alongside thiazides and renin-angiotensin system agents as acceptable first-line choices for most adults [6] [12]. Step therapy that forces amlodipine to second-line conflicts with those guidelines in many patient populations, and CMS has published guidance that step therapy protocols for Medicare Advantage plans must align with current clinical guidelines [11]. If your Humana plan is applying a step therapy requirement that your physician believes is clinically inappropriate, your physician can request a step therapy exception (also called a formulary exception) on the grounds that the required first-step drug is contraindicated, ineffective, or medically inappropriate for you specifically.

A step therapy exception request should include a letter of medical necessity from your prescriber, relevant chart notes, and any documentation of prior adverse reactions to the required first-step drug. Humana must respond within 72 hours for standard requests or 24 hours for expedited (urgent) requests [11].

How Much Does Amlodipine Cost on Humana?

With Humana Tier 1 coverage, most members pay $0 at preferred network pharmacies for generic amlodipine. Without insurance or on plans where amlodipine is not covered, the cash price is roughly $8, $15 for a 30-day supply of 5 mg tablets at major retail chains [13].

Cost varies by dose and supply. A 90-day supply of amlodipine 10 mg through Humana Pharmacy mail order costs $0, $3 on most MAPD plans for plan year 2025. For members in the catastrophic phase of Medicare Part D, out-of-pocket costs are further capped by the Inflation Reduction Act provisions effective 2025, which set a $2,000 annual out-of-pocket cap for Part D beneficiaries [14].

For comparison, brand-name Norvasc carries a manufacturer list price of approximately $80 per month [13]. Pfizer's patient assistance program (Pfizer RxPathways) may reduce cost for eligible uninsured or underinsured patients, but manufacturer copay cards generally cannot be used with federal programs including Medicare Advantage Part D [15]. That restriction is discussed further in the FAQ.

Members should also confirm whether their plan requires them to use a preferred network pharmacy. Humana's preferred pharmacy network includes Walmart, Walgreens, and Humana Pharmacy. Using an out-of-network pharmacy for a Tier 1 generic may increase the copay from $0 to $5, $20 depending on plan design [9].

What If Humana Denies Coverage for Amlodipine?

Denials for generic amlodipine are uncommon but can occur due to coding errors, plan exclusions for non-approved indications, or quantity limit conflicts. An organized, time-sensitive appeal process resolves most denials.

Step 1: Understand the denial reason. Humana sends an Explanation of Benefits (EOB) or a Notice of Denial that states the specific reason. Common reasons include: drug not on formulary for the submitted plan (plan-level issue), diagnosis code missing or not matching covered indication, quantity limit exceeded, or step therapy requirement not met [10].

Step 2: Ask your pharmacist to run a point-of-sale override. Sometimes a denial at the pharmacy counter is a billing code error. The pharmacist can contact Humana's pharmacy help desk in real time to correct a BIN/PCN routing error before a formal appeal is needed.

Step 3: Request an internal Humana appeal. Submit a written appeal to Humana's appeals and grievances department within 60 days of the denial (Medicare Advantage) or within the timeframe stated in your plan documents (commercial). Include your prescriber's letter of medical necessity, relevant clinical notes, and a copy of the denial notice [11].

Step 4: For Medicare Advantage members, escalate to an Independent Review Entity (IRE). If Humana upholds the internal denial, you may request review by MAXIMUS Federal Services, the CMS-contracted IRE for Medicare Advantage appeals [11]. MAXIMUS is required to issue a decision within 7 calendar days for standard appeals or 72 hours for expedited appeals.

Step 5: Further escalation. If MAXIMUS upholds the denial, you may escalate to an Office of Medicare Hearings and Appeals (OMHA) Administrative Law Judge, then to the Medicare Appeals Council, and finally to federal district court for amounts exceeding $1,840 (2025 threshold) [11].

The 2017 ACC/AHA hypertension guideline states: "Pharmacologic treatment of hypertension in adults with confirmed hypertension and known CVD or 10-year ASCVD event risk of 10% or higher should be initiated with a single antihypertensive drug from one of the following drug classes: thiazide-type diuretics, CCBs, ACEIs, or ARBs" [6]. Citing this language directly in an appeal letter, paired with ASCOT-BPLA outcome data [5], strengthens the medical necessity argument for amlodipine coverage when a plan attempts to substitute a different drug class.

Clinical Evidence Supporting Amlodipine Coverage

The evidence base for amlodipine is extensive and directly informs why most payers, including Humana, cover it without restriction.

ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial, N=19,257) randomized hypertensive patients with at least three additional cardiovascular risk factors to amlodipine 5 to 10 mg plus perindopril versus atenolol plus bendroflumethiazide [5]. After a median follow-up of 5.5 years, the amlodipine-based arm showed a statistically significant reduction in total cardiovascular events and procedures (rate ratio 0.84 to 95% CI 0.78, 0.90, P<0.0001) and a 24% reduction in stroke (P<0.0001) compared with the atenolol arm.

The ALLHAT trial (N=33,357) compared chlorthalidone, amlodipine, and lisinopril as initial hypertension therapy [16]. Amlodipine was non-inferior to chlorthalidone for the primary outcome of fatal coronary heart disease or nonfatal myocardial infarction (RR 0.98 to 95% CI 0.90, 1.07). Amlodipine showed superiority over lisinopril for stroke prevention in the ALLHAT population.

Meta-analyses of calcium channel blockers in hypertension confirm these single-trial findings. A 2009 Cochrane review of amlodipine for hypertension found consistent blood pressure lowering across 24 randomized trials, with a mean systolic reduction of 8 to 10 mmHg compared to placebo at 5 mg daily [17]. The FDA product label specifies efficacy for both hypertension (all ages) and chronic stable and vasospastic angina [1].

For angina specifically, amlodipine reduces angina attack frequency and nitroglycerin consumption compared to placebo in patients with chronic stable angina [1]. The AHA/ACC stable ischemic heart disease guideline recommends calcium channel blockers as first-line antianginal therapy for patients who cannot tolerate beta-blockers [18].

These trial data explain why generic amlodipine consistently earns Tier 1 placement: it is inexpensive, effective, guideline-recommended, and backed by outcomes data from trials with tens of thousands of patients.

Preferred Pharmacy Networks and Mail-Order Options

Humana's preferred pharmacy network and mail-order service directly affect the final copay for amlodipine.

Humana Pharmacy (mail order) typically offers the lowest cost-sharing for Tier 1 generics, often $0 for a 90-day supply. Walgreens is a preferred in-network retail pharmacy for most Humana plans. CVS, Walmart, and Costco pharmacies are also in-network on most Humana commercial and MAPD plans, though preferred cost-sharing may not apply at every location [9].

Filling a 90-day supply instead of 30-day supplies saves the member a pharmacy trip and often reduces per-unit cost. CMS requires Part D plans to allow 90-day supplies for maintenance medications when requested [8]. Humana Pharmacy processes 90-day fills by mail within 7, 10 business days for new prescriptions; refills process in 3, 5 business days.

If a member's preferred local pharmacy is out of Humana's preferred network, the prescriber or member can request an out-of-network exception for good cause, such as access barriers in a rural area. That exception must be submitted in writing and Humana must respond within 72 hours [11].

Special Populations and Coverage Nuances

Certain patient groups may face additional coverage considerations even for a well-established generic like amlodipine.

Pediatric hypertension. The FDA approved amlodipine for hypertension in pediatric patients ages 6, 17 at doses of 2.5 to 5 mg daily [1]. Some Humana plans apply an age-range quantity limit that defaults to the adult dosing profile and may flag pediatric prescriptions for manual review. Prescribers should include the patient's age and weight in the prescription notes to avoid a point-of-sale rejection.

Renal impairment. Amlodipine does not require dose adjustment in renal impairment, which is one reason nephrologists favor it in chronic kidney disease [4]. Humana's formulary does not apply a separate CKD-related restriction for amlodipine.

Pregnancy. Amlodipine is FDA Pregnancy Category C (old system) or risk category compatible with cautious use per ACOG guidance [19]. Humana covers amlodipine for pregnant members when prescribed for hypertension of pregnancy or chronic hypertension complicating pregnancy, consistent with ACOG guidelines.

Low-income subsidy (LIS) / Extra Help. Medicare beneficiaries who qualify for the Part D Low Income Subsidy pay $0, $4.50 per prescription for Tier 1 generics under the 2025 Extra Help program [14]. Eligible members should confirm LIS status with the Social Security Administration to ensure they receive the reduced cost-sharing.